Synthesis and biological evaluation of spiro-δ-lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2)

Letters in Drug Design and Discovery

Volumn 8, Issue 5, 2011, Pages 406-421

  Xu, Kuiying ^a   Wetzel, Marie ^a   Hartmann, Rolf W ^a,b   Marchais Oberwinkler, Sandrine ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

17 hydroxysteroid; Dehydrogenase type 2 inhibitors; Drug design; Osteoporosis; Spiro lactones; Steroidomimetics

Indexed keywords

BIPHENYL ETHYL SPIROLACTONE; HYDROXYPHENYL DIMETHYL INDANE SPIROLACTONE; HYDROXYPHENYL FLUORENE SPIROLACTONE; HYDROXYPHENYL INDANE DERIVATIVE; INDAN DERIVATIVE; LACTONE DERIVATIVE; SPIRO DELTA LACTONE DERIVATIVE; SPIRONOLACTONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 2; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG DESIGN; DRUG HALF LIFE; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 79955751501     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018011795514230     Document Type: Article

References (60)

1. Marchais-Oberwinkler, S.; Henn, C.; Möller, G.; Klein, T.; Negri, M.; Oster, A.; Spadaro, A.; Werth, R.; Wetzel, M.; Xu, K.; Frotscher, M.; Hartmann, R. W.; Adamski, J. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development. J. Steroid Biochem. Mol. Biol. 2011, in press.
2. Moeller, G.; Adamski, J. Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 2009, 301, 7-19.
3. Mindnich, R.; Möller, G.; Adamski, J. The role of 17 etahydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 2004, 218, 7-20.
4. Penning, T. M. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. Hum. Reprod. Update 2003, 9, 193-205. (Pubitemid 36827058)
5. Labrie, F.; Luu-The, V.; Lin, S. X.; Simard, J.; Labrie, C. Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab. 2000, 11, 421-427.
6. Lukacik, P.; Kavanagh, K. L.; Oppermann, U. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 2006, 248, 61-71.
7. Dong, Y.; Qiu, Q. Q.; Debear, J.; Lathrop, W. F.; Bertolini, D. R.; Tamburini, P. P. 17beta-hydroxysteroid dehydrogenases in human bone cells. J. Bone Miner. Res. 1998, 13, 1539-1546. (Pubitemid 28465294)
8. McCloskey, E. Effects of third-generation aromatase inhibitors on bone. Eur. J. Cancer 2006, 42, 1044-1051.
9. Turner, R. T.; Riggs, B. L.; Spelsberg, T. C. Skeletal effects of estrogen. Endocr. .Rev. 1994, 15, 275-300. (Pubitemid 24180788)
10. Kiel, D. P.; Felson, D. T.; Anderson, J. J.; Wilson, P. W.; Moskowitz, M. A. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N. Engl. J. Med. 1987, 317, 1169-1174. (Pubitemid 17150327)
11. Notelovitz, M. Estrogen therapy and osteoporosis: principles & practice. Am. J. Med. Sci. 1997, 313, 2-12. (Pubitemid 27036670)
12. Vanderschueren, D.; Vandenput, L.; Boonen, S.; Lindberg, M. K.; Bouillon, R.; Ohlsson, C. Androgens and bone. Endocr. Rev. 2004, 25, 389-425.
13. Vanderschueren, D.; Gaytant, J.; Boonen, S.; Venken, K. Androgens and bone. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15, 250-254.
14. Labrie, F. Intracrinology. Mol. Cell. Endocrinol. 1991, 78, C113-118.
15. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents. Mol. Cell. Endocrinol. 2009, 301, 154-157.
16. Marchais-Oberwinkler, S.; Frotscher, M.; Ziegler, E.; Werth, R.; Kruchten, P.; Messinger, J.; Thole, H.; Hartmann, R. W. Structureactivity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17betahydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors. Mol. Cell. Endocrinol. 2009, 301, 205-211.
17. Poirier, D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Curr. Med. Chem. 2003, 10, 453-477.
18. Poirier, D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anticancer Agents Med. Chem. 2009, 9, 642-660.
19. Wetzel, M.; Marchais-Oberwinkler, S.; Hartmann, R. W. 17 β - HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold. Bioorg. Med. Chem. 2011, 19, 807-815.
20. Bydal, P.; Luu-The, V.; Labrie, F.; Poirier, D. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur. J. Med. Chem. 2009, 44, 632-644.
21. Poirier, D.; Bydal, P.; Tremblay, M. R.; Sam, K. M.; Luu-The, V. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Mol. Cell. Endocrinol. 2001, 171, 119-128.
22. Sam, K. M.; Auger, S.; Luu-The, V.; Poirier, D. Steroidal spirogamma- lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes. J. Med. Chem. 1995, 38, 4518-4528.
23. Tremblay, M. R.; Luu-The, V.; Leblanc, G.; Noël, P.; Breton, E.; Labrie, F.; Poirier, D. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg. Med. Chem. 1999, 7, 1013-1023. (Pubitemid 29281601)
24. Cook, J. H.; Barzya, J.; Brennan, C.; Lowe, D.; Wang, Y.; Redman, A.; Scott, W. J.; Wood, J. E. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17β-hydroxysteroid dehydrogenase II. Part 1: Synthetic approach. Tetrahedron Lett. 2005, 46, 1525-1528. (Pubitemid 40215058)
25. Gunn, D.; Akuche, C.; Baryza, J.; Blue, M.; Brennan, C.; Campbell, A.; Choi, S.; Cook, J.; Conrad, P.; Dixon, B.; Dumas, J.; Ehrlich, P.; Gane, T.; Joe, T.; Johnson, J.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D.; McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W.; Seng, T.; Sibley, R.; Wang, M.; Wang, Y.; Wood, J.; Zhang, Z. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg. Med. Chem. Lett. 2005, 15, 3053-3057. (Pubitemid 40755196)
26. Wood, J.; Bagi, C. M.; Akuche, C.; Bacchiocchi, A.; Baryza, J.; Blue, M.; Brennan, C.; Campbell, A.; Choi, S.; Cook, J. H.; Conrad, P.; Dixon, B. R.; Ehrlich, P. P.; Gane, T.; Gunn, D.; Joe, T.; Johnson, J. S.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D. B.; McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W. J.; Town, C.; Wang, M.; Wang, Y.; Zhang, Z. 4,5-Disubstituted cispyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. Bioorg. Med. Chem. Lett. 2006, 16, 4965-4968. (Pubitemid 44175841)
27. Bagi, C. M.; Wood, J.; Wilkie, D.; Dixon, B. Effect of 17betahydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys. J. Musculoskelet. Neuronal Interact. 2008, 8, 267-280.
28. Cavalli, A.; Bisi, A.; Bertucci, C.; Rosini, C.; Paluszcak, A.; Gobbi, S.; Giorgio, E.; Rampa, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Hartmann, R. W.; Recanatini, M. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J. Med. Chem. 2005, 48, 7282-7289. (Pubitemid 41743641)
29. Hartmann, R. W.; Frotscher, M.; Ledergerber, D.; Wächter, G. A.; Grün, G. L.; Sergejew, T. F. Synthesis and evaluation of azolesubstituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2. Arch. Pharm. 1996, 329, 251-261. (Pubitemid 26186124)
30. Wächter, G. A.; Hartmann, R. W.; Sergejew, T.; Grün, G. L.; Ledergerber, D. Tetrahydronaphthalenes: influence of heterocyclic substituents on inhibition of steroid enzymes P450 arom and P450 17. J. Med. Chem. 1996, 39, 834-841. (Pubitemid 26069779)
31. Picard, F.; Schulz, T.; Hartmann, R. W. 5-Phenyl substituted 1- methyl-2-pyridones and 4'-substituted biphenyl-4-carboxylic acids. synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2. Bioorg. Med. Chem. 2002, 10, 437-448. (Pubitemid 33121268)
32. Baston, E.; Hartmann, R. W. N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity. Bioorg. Med. Chem. Lett. 1999, 9, 1601-1606. (Pubitemid 29274205)
33. Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Jagusch, C.; Müller- Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer. J. Med. Chem. 2008, 51, 5009-5018.
34. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Müller- Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls. Eur J. Med. Chem. 2009, 44, 2765-2775.
35. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Marchais-Oberwinkler, S.; Hartmann, R. W. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J. Med. Chem. 2005, 48, 6632-6642. (Pubitemid 41504720)
36. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J. Med. Chem. 2008, 51, 6138-6149.
37. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin- 2-one derivatives. J. Med. Chem. 2008, 51, 8077-8087.
38. Lucas, S., Negri, M., Heim, R., Zimmer, C., Hartmann, R.W., Finetuning the selectivity of aldosterone synthase inhibitors: Structureactivity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo [3,2,1-ij]quinolin-4-one derivatives, J. Med. Chem. 2011, in press.
39. Heim, R., Lucas, S., Grombein, C.M., Ries, C.,Schewe, K.E., Negri, M., Müller-Vieira, U., jBirk, B., Hartmann, R.W., Overcoming undesirable CYP1A2 potency of pyridylnaphthalene type aldosterone synthase inhibitors: Influence of heteroaryl substitution on potency and selectivity, J. Med. Chem. 2008, 51, 5064-5074.
40. Hille, U.E.; Zimmer, C.; Vock, C.A.; Hartmann, R.W., First selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases, Med. Chem. Lett. 2011, 2, 2-6.
41. Hille, U.E., Zimmer, C., Haupenthal, J., Hartmann, R.W., Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases, Med. Chem. Lett. 2011, in press.
42. Frotscher, M.; Ziegler, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Neugebauer, A.; Fetzer, L.; Scherer, C.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 2008, 51, 2158-2169. (Pubitemid 351503271)
43. Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Ziegler, E.; Neugebauer, A.; Bhoga, U.; Bey, E.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17betahydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. J. Med. Chem. 2008, 51, 4685-4698.
44. Bey, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Werth, R.; Oster, A.; Algül, O.; Neugebauer, A.; Hartmann, R. W. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17betahydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bioorg. Med. Chem. 2008, 16, 6423-6435. (Pubitemid 351783414)
45. Bey, E.; Marchais-Oberwinkler, S.; Werth, R.; Negri, M.; Al-Soud, Y. A.; Kruchten, P.; Oster, A.; Frotscher, M.; Birk, B.; Hartmann, R. W. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J. Med. Chem. 2008, 51, 6725-6739.
46. Al-Soud, Y. A.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Werth, R.; Kruchten, P.; Frotscher, M.; Hartmann, R. W. The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2. Mol. Cell. Endocrinol. 2009, 301, 212-215.
47. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Bey, E.; Ziegler, E.; Oster, A.; Frotscher, M.; Hartmann, R. W. Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations. Comptes Rendus Chimie 2009, 12, 1110-1116.
48. Kruchten, P.; Werth, R.; Bey, E.; Oster, A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Selective inhibition of 7betahydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. J. Steroid Biochem. Mol. Biol. 2009, 114, 200-206.
49. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; Spadaro, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. J. Med. Chem. 2009, 52, 6724-6743.
50. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg. Med. Chem. 2010, 18, 3494-3505.
51. Oster, A.; Hinsberger, S.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 2010, 53, 8176-8186.
52. Negri, M.; Recanatini, M.; Hartmann, R. W. Insights in 17beta- HSD1 enzyme kinetics and ligand binding by dynamic motion investigation. PLoS ONE 2010, 5, e12026.
53. Marchais-Oberwinkler, S.; Wetzel, M.; Ziegler, E.; Kruchten, P.; Werth, R.; Henn, C.; Hartmann, R. W.; Frotscher, M. New druglike hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases. J. Med. Chem. 2011, 54, 534-547.
54. Oster, A.; Klein, T.; Henn, C.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bicyclic Substituted Hydroxyphenylmethanone Type Inhibitors of 17ββ-Hydroxysteroid Dehydrogenase Type 1 (17ββ-HSD1): The Role of the Bicyclic Moiety. ChemMedChem 2011, in press.
55. Allan, G. M.; Vicker, N.; Lawrence, H. R.; Tutill, H. J.; Day, J. M.; Huchet, M.; Ferrandis, E.; Reed, M. J.; Purohit, A.; Potter, B. V. L. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. Bioorg. Med. Chem. 2008, 16, 4438-4456. (Pubitemid 351545841)
56. Mewshaw, R. E.; Edsall, R. J.; Yang, C.; Manas, E. S.; Xu, Z. B.; Henderson, R. A.; Keith, J. C.; Harris, H. A. ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J. Med. Chem. 2005, 48, 39853-3979.
57. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Tetrapropylammonium Perruthenate, Pr4N+O4 -, TPAP: A Catalytic Oxidant for Organic Synthesis. Synthesis 1994, 1994, 639-666. (Pubitemid 24240467)
58. Chordia, M. D.; Zigler, M.; Murphree, L. J.; Figler, H.; Macdonald, T. L.; Olsson, R. A.; Linden, J. 6-Aryl-8H-indeno[1,2-d]thiazol-2-ylamines:β A1 Adenosine Receptor Agonist Allosteric Enhancers Having Improved Potency. J. Med. Chem. 2005, 48, 5131-5139. (Pubitemid 41113901)
59. Grisorio, R.; Mastrorilli, P.; Ciccarella, G.; Suranna, G. P.; Nobile, C. F. Synthesis and optical behaviour of monodispersed oligo(fluorenylidene)s. Tetrahedron Lett. 2008, 49, 2078-2082.
60. Lin, S. X.; Yang, F.; Jin, J. Z.; Breton, R.; Zhu, D. W.; Luu-The, V.; Labrie, F. Subunit identity of the dimeric 17 betahydroxysteroid dehydrogenase from human placenta. J. Biol. Chem. 1992, 267, 16182-16187.